NASDAQ:HOTH Hoth Therapeutics - HOTH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.94 +0.01 (+0.20%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.81▼$5.0550-Day Range$2.96▼$10.7252-Week Range$2.61▼$40.74Volume47,140 shsAverage Volume100,711 shsMarket Capitalization$7.11 millionP/E RatioN/ADividend YieldN/APrice Target$66.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Hoth Therapeutics (NASDAQ:HOTH) StockHoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.Read More Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOTH Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comHoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyDecember 30, 2022 | benzinga.comThinking about buying stock in Mullen Automotive, Hoth Therapeutics, Futu Holdings, Shaw Communications, or Ardelyx?February 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 30, 2022 | nasdaq.comHoth Therapeutics Rises On FDA Accepting IND For Its HT-001 TherapeuticDecember 30, 2022 | marketwatch.comHoth Therapeutics Shares Double, FDA Accepts New Drug Application for Skin TreatmentDecember 30, 2022 | msn.comWhy Hoth Therapeutics Shares Are NosedivingDecember 30, 2022 | marketwatch.comHoth Therapeutics Shares Drop 26% on Discounted Private Share PlacementDecember 30, 2022 | msn.comEF Hutton Maintains Buy Rating for Hoth Therapeutics: Here's What You Need To KnowFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 29, 2022 | msn.comWhy Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day SessionDecember 29, 2022 | finance.yahoo.comFDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin CancersDecember 29, 2022 | msn.comHoth Therapeutics surges 35% on FDA nod to begin trial of treatment for skin disorders in cancer patientsDecember 29, 2022 | marketwatch.comHoth Therapeutics Shares Rise 77% After FDA Accepts IND for HT-001December 29, 2022 | markets.businessinsider.comHoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer DisordersDecember 29, 2022 | finance.yahoo.comHoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor TherapyDecember 1, 2022 | finance.yahoo.comHoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001November 9, 2022 | finance.yahoo.comHoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNovember 1, 2022 | investorplace.comWhy Is Hoth Therapeutics (HOTH) Stock Up 24% Today?October 31, 2022 | msn.comWhat's Going On With Hoth Therapeutics Stock?October 31, 2022 | marketwatch.comHoth Therapeutics Shares Rise 30% After Positive Data for BioLexa TrialOctober 31, 2022 | finance.yahoo.comHOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITISOctober 31, 2022 | finance.yahoo.comHoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares JumpOctober 25, 2022 | msn.comWhy Crown Holdings Shares Are Trading Lower By Around 22%? Here Are 46 Stocks Moving In Tuesday's Mid-Day SessionOctober 25, 2022 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.07%October 25, 2022 | msn.comUS Futures Mixed Ahead of Consumer Confidence, House Price DataOctober 24, 2022 | marketwatch.comHoth Therapeutics Shares Fall 20% After Reverse-Split NewsOctober 24, 2022 | finance.yahoo.comHoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOTH Company Calendar Last Earnings11/10/2022Today2/04/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOTH CUSIPN/A CIK1711786 Webwww.hoththerapeutics.com Phone(646) 756-2997FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$66.50 High Stock Price Forecast$100.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+1,246.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-121.00% Return on Assets-108.13% Debt Debt-to-Equity RatioN/A Current Ratio9.43 Quick Ratio9.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.31 per share Price / Book0.48Miscellaneous Outstanding Shares1,440,000Free Float1,286,000Market Cap$7.11 million OptionableNot Optionable Beta0.08 Key ExecutivesRobbie KnieChairman, President & Chief Executive OfficerHayley SpringerVice President-OperationsDavid S. BrionesChief Financial & Accounting OfficerStefanie JohnsChief Scientific OfficerMaryBeth JonesDirector-Project ManagementKey CompetitorsCohBarNASDAQ:CWBRPLx PharmaNASDAQ:PLXPTimber PharmaceuticalsNYSE:TMBRPhio PharmaceuticalsNASDAQ:PHIOExicureNASDAQ:XCURView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 177,659 shares on 11/15/2022Ownership: 72.485%Renaissance Technologies LLCSold 21,200 shares on 11/14/2022Ownership: 10.563%Robb KnieBought 10,000 shares on 9/19/2022Total: $3,900.00 ($0.39/share)Robb KnieBought 10,000 shares on 9/19/2022Total: $3,900.00 ($0.39/share)Robb KnieBought 10,000 shares on 9/16/2022Total: $4,000.00 ($0.40/share)View All Insider TransactionsView All Institutional Transactions HOTH Stock - Frequently Asked Questions Should I buy or sell Hoth Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOTH shares. View HOTH analyst ratings or view top-rated stocks. What is Hoth Therapeutics' stock price forecast for 2023? 1 brokers have issued 1-year price objectives for Hoth Therapeutics' stock. Their HOTH share price forecasts range from $33.00 to $100.00. On average, they predict the company's stock price to reach $66.50 in the next twelve months. This suggests a possible upside of 1,246.2% from the stock's current price. View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts. How have HOTH shares performed in 2023? Hoth Therapeutics' stock was trading at $7.80 at the start of the year. Since then, HOTH shares have decreased by 36.7% and is now trading at $4.94. View the best growth stocks for 2023 here. When is Hoth Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our HOTH earnings forecast. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its earnings results on Thursday, November, 10th. The company reported ($2.05) earnings per share for the quarter. When did Hoth Therapeutics' stock split? Shares of Hoth Therapeutics reverse split on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV). When did Hoth Therapeutics IPO? (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO. What is Hoth Therapeutics' stock symbol? Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH." How do I buy shares of Hoth Therapeutics? Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hoth Therapeutics' stock price today? One share of HOTH stock can currently be purchased for approximately $4.94. How much money does Hoth Therapeutics make? Hoth Therapeutics (NASDAQ:HOTH) has a market capitalization of $7.11 million. The company earns $-14,310,000.00 in net income (profit) each year or ($10.55) on an earnings per share basis. How can I contact Hoth Therapeutics? Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The official website for the company is www.hoththerapeutics.com. The company can be reached via phone at (646) 756-2997 or via email at investorrelations@hoththerapeutics.com. This page (NASDAQ:HOTH) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.